465 related articles for article (PubMed ID: 27342909)
21. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Beltran H; Wyatt AW; Chedgy EC; Donoghue A; Annala M; Warner EW; Beja K; Sigouros M; Mo F; Fazli L; Collins CC; Eastham J; Morris M; Taplin ME; Sboner A; Halabi S; Gleave ME
Clin Cancer Res; 2017 Nov; 23(22):6802-6811. PubMed ID: 28842510
[No Abstract] [Full Text] [Related]
22. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
[TBL] [Abstract][Full Text] [Related]
23. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
24. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
Graff RE; Pettersson A; Lis RT; DuPre N; Jordahl KM; Nuttall E; Rider JR; Fiorentino M; Sesso HD; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Nguyen PL; Sweeney CJ; Mucci LA;
Prostate; 2015 Jun; 75(9):897-906. PubMed ID: 25728532
[TBL] [Abstract][Full Text] [Related]
25. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
26. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
27. Functional heterogeneity of prostatic intraepithelial neoplasia: the duration of hormonal therapy influences the response.
Kang TY; Nichols P; Skinner E; Groshen S; Valin G; Ye W; Raghavan D
BJU Int; 2007 May; 99(5):1024-7. PubMed ID: 17244277
[TBL] [Abstract][Full Text] [Related]
28. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression.
Salah Z; Maoz M; Cohen I; Pizov G; Pode D; Runge MS; Bar-Shavit R
FASEB J; 2005 Jan; 19(1):62-72. PubMed ID: 15629896
[TBL] [Abstract][Full Text] [Related]
30. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
31. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
[TBL] [Abstract][Full Text] [Related]
32. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
33. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
34. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Dahlman A; Edsjö A; Halldén C; Persson JL; Fine SW; Lilja H; Gerald W; Bjartell A
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):369-75. PubMed ID: 20680031
[TBL] [Abstract][Full Text] [Related]
35. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
36. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
37. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
Bonaccorsi L; Nesi G; Nuti F; Paglierani M; Krausz C; Masieri L; Serni S; Proietti-Pannunzi L; Fang Y; Jhanwar SC; Orlando C; Carini M; Forti G; Baldi E; Luzzatto L
J Endocrinol Invest; 2009 Jul; 32(7):590-6. PubMed ID: 19494719
[TBL] [Abstract][Full Text] [Related]
38. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.
Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC
BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431
[TBL] [Abstract][Full Text] [Related]
39. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
40. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
